AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2438924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol hydrochloride 300 mg/day
Number of subjects: 0
Study 2438924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol hydrochloride 400 mg/day
Number of subjects: 0
Study 2438924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30097702 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene (200 ppm)
Number of subjects: 17
Study 30097702 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 17
Study 28566338 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) graft
Number of subjects: 2737
Study 28566338 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 2737
Study 24478320 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 24478320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22399700 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise (30 min of cycling exercise at 50% maximal workload capacity)
Number of subjects: 30
Study 22399700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performed every other day (60 min of cycling exercise at 50% maximal workload capacity)
Number of subjects: 30
Study 22399700 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 30
Study 20808252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 0
Study 20808252 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0
Study 17961015 — intervention group
Group type: EXPERIMENTAL
Intervention: Section of the terminal filum
Number of subjects: 0
Study 17961015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15503125 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal apneas (3 apneas separated by 2 min rest)
Number of subjects: 10
Study 12552940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 505
Study 12552940 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensification chemotherapy
Number of subjects: 505
Study 12552940 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE regimen (ifosfamide, carboplatin, etoposide) and CBP regimen (cyclophosphamide, cisplatin, carmustine)
Number of subjects: 505
Study 9808381 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 40
Study 9808381 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 40
Study 7596208 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality evaluation tool
Number of subjects: 101
Study 1922869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative caloric sources (branched chain amino acids, fatty acids, ketonic bodies)
Number of subjects: 0
Study 353680 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications
Number of subjects: 26
Study 353680 — intervention group
Group type: COMPARATOR
Intervention: Placebo medications
Number of subjects: 26
Study 353680 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (cookies without artificial colors)
Number of subjects: 26
Study 353680 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (cookies with artificial colors)
Number of subjects: 26
Study 31348351 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 0
Study 31348351 — intervention group
Group type: COMPARATOR
Intervention: Non-virtual reality
Number of subjects: 0
Study 27910156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every 4 weeks after a 160 mg starting dose)
Number of subjects: 1346
Study 27910156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every 2 weeks after a 160 mg starting dose)
Number of subjects: 1346
Study 27910156 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 1346
Study 27910156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1346
Study 25367222 — intervention group
Group type: EXPERIMENTAL
Intervention: BF‐FES + mirror therapy
Number of subjects: 29
Study 25367222 — intervention group
Group type: EXPERIMENTAL
Intervention: FES + mirror therapy
Number of subjects: 29
Study 25367222 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional physical therapy program)
Number of subjects: 29
Study 23794414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (5 to 240 mg)
Number of subjects: 745
Study 21807150 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric joystick
Number of subjects: 20
Study 21807150 — intervention group
Group type: COMPARATOR
Intervention: Conventional joystick
Number of subjects: 20
Study 19187411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (approximately 4,000 lux)
Number of subjects: 51
Study 19187411 — intervention group
Group type: COMPARATOR
Intervention: Dim light (approximately 65 lux)
Number of subjects: 51
Study 16899731 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activity in the ventromedial prefrontal cortex (vmPFC) during decision-making task.
Number of subjects: 0
Study 17097350 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter Alyx (AX)
Number of subjects: 30
Study 17097350 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics MCS Plus (MCS+)
Number of subjects: 30
Study 17097350 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambro Trima Accel (TA)
Number of subjects: 30
Study 12927001 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 150 mg/day)
Number of subjects: 52
Study 12927001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 100 mg/day)
Number of subjects: 52
Study 10071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete objective information (in addition to usual information)
Number of subjects: 43
Study 10071702 — intervention group
Group type: COMPARATOR
Intervention: Usual information
Number of subjects: 43
Study 10071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 7645699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen administration (up to 6 l.min‐1)
Number of subjects: 0
Study 7645699 — intervention group
Group type: EXPERIMENTAL
Intervention: Position of the sampling catheter
Number of subjects: 0
Study 7645699 — intervention group
Group type: COMPARATOR
Intervention: Mouth breathing
Number of subjects: 0
Study 2144019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 5 mg/m2 IV (group A)
Number of subjects: 20
Study 2144019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 3 mg/m2 IV (group B)
Number of subjects: 20
Study 7009593 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2.2 mg daily for 21 days)
Number of subjects: 46
Study 7009593 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (20.2 mg daily for 21 days)
Number of subjects: 46
Study 31387097 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat in treatment-naïve patients not on dialysis
Number of subjects: 0
Study 31387097 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat in previously ESA-treated patients not on dialysis
Number of subjects: 0
Study 31387097 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat in previously ESA-treated patients receiving hemodialysis
Number of subjects: 0
Study 31387097 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat in patients not receiving iron supplementation
Number of subjects: 0
Study 28470100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg (D1)
Number of subjects: 100
Study 28470100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (D2)
Number of subjects: 100
Study 28470100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg (D3)
Number of subjects: 100
Study 28470100 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study 25585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister method (session 1)
Number of subjects: 16
Study 25585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister method (session 2)
Number of subjects: 16
Study 25585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister method (sessions 1 and 2)
Number of subjects: 16
Study 23294670 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria-infected individuals (low, medium, high density of P. falciparum)
Number of subjects: 231
Study 23294670 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria-infected individuals
Number of subjects: 231
Study 23294670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitogen-activated T-cell populations
Number of subjects: 231
Study 23294670 — intervention group
Group type: COMPARATOR
Intervention: N/A (impact of A. lumbricoides)
Number of subjects: 231
Study 21849729 — intervention group
Group type: EXPERIMENTAL
Intervention: DD current therapy
Number of subjects: 80
Study 21849729 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 80
Study 21849729 — intervention group
Group type: COMPARATOR
Intervention: Control group (functional fitness test)
Number of subjects: 80
Study 18472391 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Everyday Attention for Children (TEA‐Ch)
Number of subjects: 232
Study 16278260 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) plus testosterone (T) implants
Number of subjects: 80
Study 16278260 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) implants alone
Number of subjects: 80
Study 12921985 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine concentration >12 micromol/l
Number of subjects: 231
Study 12921985 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte S-adenosylmethionine concentration >4000 nmol/l
Number of subjects: 231
Study 11079650 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 220
Study 11079650 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 220
Study 11079650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 220
Study 8677737 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF/IL‐3 combination
Number of subjects: 0
Study 8677737 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 0
Study 1570609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gram intravenously 30 minutes prior to skin incision)
Number of subjects: 292
Study 1570609 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 gram intravenously 30 minutes prior to skin incision)
Number of subjects: 292
Study 1570609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 292
Study 1570609 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 292
Study 6691892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 24
Study 28833227 — intervention group
Group type: EXPERIMENTAL
Intervention: positive imagery
Number of subjects: 159
Study 28833227 — intervention group
Group type: EXPERIMENTAL
Intervention: imagery reexperiencing
Number of subjects: 159
Study 28833227 — intervention group
Group type: EXPERIMENTAL
Intervention: imagery rescripting
Number of subjects: 159
Study 28833227 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 27061302 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based care (use of four validated screening tools: PEDS, PEDS-DM, M-CHAT, PHQ9)
Number of subjects: 54
Study 27061302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (informal judgment including ad-hoc milestones)
Number of subjects: 54
Study 23962728 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 50
Study 23962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 50
Study 23962728 — intervention group
Group type: COMPARATOR
Intervention: Laccase
Number of subjects: 50
Study 22689807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 291
Study 22689807 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib monotherapy
Number of subjects: 291
Study 19930768 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER)
Number of subjects: 137
Study 19930768 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction with resistance training (ER+RT)
Number of subjects: 137
Study 19930768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropouts
Number of subjects: 137
Study 18701183 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time continuous glucose monitoring system (RT‐CGM)
Number of subjects: 65
Study 18701183 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitoring blood glucose (SMBG)
Number of subjects: 65
Study 16012272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 20
Study 16012272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12488257 — intervention group
Group type: EXPERIMENTAL
Intervention: New topical cysteamine formulation
Number of subjects: 36
Study 12488257 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of topical cysteamine
Number of subjects: 36
Study 11817492 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid taper algorithm (phase 2)
Number of subjects: 106
Study 11817492 — intervention group
Group type: COMPARATOR
Intervention: No study intervention (phase 1)
Number of subjects: 106
Study 10026666 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM) intervention
Number of subjects: 2
Study 10026666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2
Study 7572652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical exercise (> 3 hours/week) and low-fat diet
Number of subjects: 113
Study 7572652 — intervention group
Group type: COMPARATOR
Intervention: Usual care by private physicians (Control)
Number of subjects: 113
Study 1968355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SASP)
Number of subjects: 30
Study 1968355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7258124 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial multivitamin‐multimineral supplement
Number of subjects: 16
Study 7258124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31800880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup probe group (CPG)
Number of subjects: 25
Study 31800880 — intervention group
Group type: COMPARATOR
Intervention: Finger probe group (FPG)
Number of subjects: 25
Study 28296771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (group 2, n=63)
Number of subjects: 137
Study 28296771 — intervention group
Group type: COMPARATOR
Intervention: Video demonstration (group 1, n=74)
Number of subjects: 137
Study 26338040 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily
Number of subjects: 1029
Study 26338040 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1029
Study 24768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE)
Number of subjects: 134
Study 24768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing problems
Number of subjects: 134
Study 24768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing problems (among girls)
Number of subjects: 134
Study 24768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and perceived peer drug use
Number of subjects: 134
Study 22040533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC) 250/50 mcg twice daily
Number of subjects: 0
Study 22040533 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg once daily
Number of subjects: 0
Study 18596686 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 22
Study 18596686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17692354 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of PCBs and other persistent organohalogen pollutants (POPs)
Number of subjects: 310
Study 15539049 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TR)
Number of subjects: 29
Study 15539049 — intervention group
Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 29
Study 11133316 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory task with mixed 'blocked and event-related' design
Number of subjects: 0
Study 9509948 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of membranes
Number of subjects: 100
Study 9509948 — intervention group
Group type: COMPARATOR
Intervention: Gentle cervical examination (Control)
Number of subjects: 100
Study 7999928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus of 120 ms
Number of subjects: 105
Study 7999928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus of 200 ms
Number of subjects: 105
Study 7999928 — intervention group
Group type: COMPARATOR
Intervention: Blink stimulus alone (control)
Number of subjects: 105
Study 7999928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus of 30, 60, 120, 240, 500 ms
Number of subjects: 105
Study 7999928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus of 2000 ms
Number of subjects: 105
Study 3052064 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15
Study 3052064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 15
Study 3052064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30079876 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) with chance-based uncertainty (gamified spinners)
Number of subjects: 141
Study 30079876 — intervention group
Group type: COMPARATOR
Intervention: Web-based Personalized Normative Feedback (PNF) without chance-based uncertainty (no-spinner alcohol-only condition)
Number of subjects: 141
Study 27930779 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit-based visual rehabilitation intervention (n = 35)
Number of subjects: 67
Study 27930779 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control arm (n = 32)
Number of subjects: 67
Study 23975326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g oil (rapeseed) with 3 μm droplet size
Number of subjects: 24
Study 23975326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g oil (rapeseed) with 0.1 μm droplet size
Number of subjects: 24
Study 23975326 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g oil (rapeseed) with 3 μm droplet size
Number of subjects: 24
Study 23975326 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g oil (rapeseed) with 0.1 μm droplet size
Number of subjects: 24
Study 22520250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily
Number of subjects: 423
Study 22520250 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 423
Study 22520250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 423
Study 22520250 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 423
Study 20882867 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 0
Study 20882867 — intervention group
Group type: COMPARATOR
Intervention: Verbal response (Control)
Number of subjects: 0
Study 17129761 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with heavy rugby balls
Number of subjects: 14
Study 17129761 — intervention group
Group type: COMPARATOR
Intervention: Training with normal rugby balls
Number of subjects: 14
Study 16189334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg pre-incision
Number of subjects: 60
Study 16189334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg post-incision
Number of subjects: 60
Study 16189334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16040729 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution applied every 6 months for 36 months
Number of subjects: 425
Study 16040729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDF treatment)
Number of subjects: 425
Study 10949635 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised studies
Number of subjects: 0
Study 10949635 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised studies
Number of subjects: 0
Study 9236963 — intervention group
Group type: EXPERIMENTAL
Intervention: Contests
Number of subjects: 55
Study 9236963 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct education
Number of subjects: 55
Study 9236963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive activities
Number of subjects: 55
Study 9236963 — intervention group
Group type: COMPARATOR
Intervention: Kickoff event
Number of subjects: 55
Study 9236963 — intervention group
Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 55
Study 8470424 — intervention group
Group type: EXPERIMENTAL
Intervention: NIB-14 vaccine
Number of subjects: 0
Study 8470424 — intervention group
Group type: EXPERIMENTAL
Intervention: NIB-17 vaccine
Number of subjects: 0
Study 8470424 — intervention group
Group type: COMPARATOR
Intervention: Cross-reactive antibodies
Number of subjects: 0
Study 2879960 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily) during intravenous clorazepate administration
Number of subjects: 19
Study 2879960 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 19
Study 2456682 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoton (phosphocreatine)
Number of subjects: 60
Study 2456682 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27331601 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Natural Language Processing (NLP) algorithm
Number of subjects: 0
Study 27331601 — intervention group
Group type: COMPARATOR
Intervention: Manual records review
Number of subjects: 0
Study 27331601 — intervention group
Group type: COMPARATOR
Intervention: Incident reporting system
Number of subjects: 0
Study 31173409 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13